Corticosteroids in Non-Viral Acute Respiratory Distress Syndrome: Research Highlights Disparities in Therapeutic Approaches

Strategic Insights -

Research conducted by the Faculty of Medicine at Nam Can Tho University has shed light on the complexities of using corticosteroids in non-viral acute respiratory distress syndrome (ARDS). According to the study, the 2024 global redefinition of ARDS has broadened diagnostic criteria to include patients on non-invasive respiratory support, introducing heterogeneity in disease severity, inflammatory burden, and treatment responsiveness. Despite recent guidelines recommending corticosteroids for moderate-to-severe ARDS, key questions persist regarding optimal timing, dosing, and patient selection.

Key Takeaways:

  • The 2024 global redefinition of ARDS includes patients on non-invasive respiratory support, increasing heterogeneity in disease severity and treatment responsiveness.
  • Recent guidelines recommend corticosteroids for moderate-to-severe ARDS, but lack specificity on optimal timing, dosing, and patient selection.
  • The DEXA-ARDS trial demonstrated that high-dose dexamethasone reduced mortality in moderate-to-severe ARDS, but its generalizability to less severe or non-intubated patients is unclear.
  • Hydrocortisone regimens used in the CAPE-COD and APROCCHSS trials showed mortality benefits in severe community-acquired pneumonia, suggesting a therapeutic niche for corticosteroids in non-viral, infection-associated ARDS.
  • A recent network meta-analysis suggests that low-dose methylprednisolone may reduce ARDS mortality, but phenotype-specific efficacy is not well-defined.
  • Clinicians must balance empirical benefit with thoughtful restraint in applying corticosteroids to non-viral ARDS due to current evidence gaps and nuanced ARDS subtypes.
  • Precision approaches for corticosteroid use in non-viral ARDS are still undefined, necessitating a cautious approach to individual therapy.

Statistics:

  • The 2024 global redefinition of ARDS includes patients on non-invasive respiratory support.
  • Recent guidelines recommend corticosteroids for moderate-to-severe ARDS.
  • The DEXA-ARDS trial involved a high-dose dexamethasone regimen.
  • Hydrocortisone regimens used in the CAPE-COD and APROCCHSS trials showed mortality benefits in severe community-acquired pneumonia.
  • A recent network meta-analysis suggests that low-dose methylprednisolone may reduce ARDS mortality.

Sources:

  • Nguyen, T. L., Pham, P. T., Duong, V. P., & Duong, H. N. T. (2025). Corticosteroids in non-viral acute respiratory distress syndrome (ARDS): recommendations outpace evidence - a concise review. Pneumonia, 17(1), 1-5. doi: 10.1186/s41479-025-00183-x
  • NewsRx. New Findings from Faculty of Medicine Describe Advances in Acute Respiratory Distress Syndrome [Corticosteroids in non-viral acute respiratory distress syndrome (ARDS): recommendations outpace evidence - a concise review]. Respiratory Therapeutics Week. October 20, 2025; p 2739.